Ignite Creation Date:
2025-12-25 @ 2:32 AM
Ignite Modification Date:
2026-02-08 @ 12:31 AM
Study NCT ID:
NCT01990534
Status:
COMPLETED
Last Update Posted:
2021-04-09
First Post:
2013-11-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Sponsor:
Millennium Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hodgkin Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Lymphoma | View |
| None | Hodgkin | View |
| None | Relapsed | View |
| None | Refractory | View |
| None | Antigens, CD30 | View |
| None | Antibody-Drug Conjugate | View |
| None | Antibodies, Monoclonal | View |
| None | Monomethyl auristatin E | View |
| None | Drug Therapy | View |
| None | Immunotherapy | View |
| None | Hematologic Diseases | View |
| None | Additional Relevant MeSH terms: | View |
| None | Lymphoma, Large B-Cell, Diffuse | View |
| None | Lymphoma, Hodgkin | View |
| None | Neoplasms by Histologic Type | View |
| None | Neoplasms | View |
| None | Lymphoproliferative Disorders | View |
| None | Lymphatic Diseases | View |
| None | Immunoproliferative Disorders | View |
| None | Immune System Diseases | View |
| None | Lymphoma, B-Cell | View |
| None | Lymphoma, T-Cell | View |
| None | Immunologic Factors | View |
| None | Physiological Effects of Drugs | View |
| None | Pharmacologic Actions | View |